What deprescribing plan should be used for a patient taking fluoxetine 20 mg daily, vortioxetine, trazodone, temazepam, and hydroxyzine who already has scheduled ophthalmology appointments?

Deprescribing Plan for Multiple Psychotropic Medications with Scheduled Ophthalmology Follow-up

Given that ophthalmology appointments are already scheduled, prioritize immediate discontinuation of medications with anticholinergic burden (hydroxyzine, trazodone) and address the concerning polypharmacy of multiple serotonergic agents (fluoxetine, vortioxetine, trazodone) that increases serotonin syndrome risk, while tapering benzodiazepines (temazepam) slowly to avoid withdrawal.

Immediate Safety Concerns

Serotonin Syndrome Risk

This patient is taking three serotonergic medications simultaneously (fluoxetine, vortioxetine, trazodone), which significantly elevates the risk of serotonin syndrome. Guidelines explicitly warn that combining multiple non-MAOI serotonergic drugs requires extreme caution, with monitoring especially critical in the first 24-48 hours after dosage changes 1. This polypharmacy regimen is inappropriate and requires urgent rationalization.

Anticholinergic Burden

Both hydroxyzine and trazodone contribute to anticholinergic burden, which adversely affects cognition, vision, urination, and constipation in patients 2. Hydroxyzine should be eliminated immediately as it provides minimal benefit in this context and adds unnecessary anticholinergic effects 2.

Structured Deprescribing Algorithm

Step 1: Discontinue Hydroxyzine Immediately

• Action: Stop hydroxyzine without taper (short half-life, minimal withdrawal risk)
• Rationale: Strong anticholinergic properties poorly tolerated; contributes to medication burden without clear indication 2
• Timeline: Immediate discontinuation

Step 2: Taper and Discontinue Trazodone (Weeks 1-4)

• Week 1-2: Reduce trazodone by 50% of current dose
• Week 3-4: Reduce to 25% of original dose, then discontinue
• Rationale: Trazodone adds serotonergic activity and anticholinergic effects; if used for sleep, address with non-pharmacological interventions (CBT-Insomnia, sleep hygiene) 3
• Monitor: Sleep quality, mood stability

Step 3: Rationalize Antidepressant Therapy (Weeks 5-8)

Choose ONE primary antidepressant based on:

• Fluoxetine advantages: Longest half-life (4-6 days), facilitates easier discontinuation if needed, FDA-approved for multiple indications 4, 5
• Vortioxetine disadvantages: Requires monitoring for angle-closure glaucoma (relevant given scheduled eye appointments), more sexual dysfunction 6

Recommended approach: Discontinue vortioxetine, maintain fluoxetine 20 mg daily

Vortioxetine taper (given scheduled ophthalmology appointments make this medication particularly concerning):

• Week 5-6: Reduce vortioxetine by 50%
• Week 7-8: Reduce to 25%, then discontinue
• Rationale: Vortioxetine carries specific risk of angle-closure glaucoma requiring preventative ophthalmologic evaluation 6; fluoxetine's long half-life provides natural buffering against withdrawal 5, 7

Step 4: Temazepam Taper (Weeks 9-20, Minimum)

Critical principle: Benzodiazepines require slow, hyperbolic tapering with flexible, gradual dose reductions to minimize withdrawal 8

• Weeks 9-12: Reduce by 10-15% of current dose
• Weeks 13-16: Reduce by another 10-15%
• Weeks 17-20: Continue 10-15% reductions every 3-4 weeks
• Reversion protocol: If withdrawal symptoms emerge (anxiety, insomnia, tremor, seizures), return to previous dose and slow taper further 8
• Adjunctive support: Offer CBT-Insomnia and peer-support resources 8
• Timeline flexibility: May require 6-12 months for complete discontinuation depending on duration of use and patient tolerance

Monitoring Parameters

Weeks 1-4 (Hydroxyzine/Trazodone Discontinuation)

• Sleep quality and duration
• Anxiety symptoms
• Cognitive function
• Vision changes

Weeks 5-8 (Vortioxetine Discontinuation)

• Discontinuation syndrome symptoms: Dizziness, fatigue, headaches, nausea, sensory disturbances, anxiety 1
• Mood stability (depression rating scales)
• Sexual function changes
• Ophthalmology findings: Ensure eye examination completed, monitor for angle-closure glaucoma symptoms (eye pain, vision changes, redness) 6

Weeks 9-20+ (Temazepam Taper)

• Withdrawal symptoms: Anxiety, insomnia, tremor, confusion, seizure risk
• Sleep architecture
• Functional status
• Cognitive performance

Final Maintenance Regimen

Target: Fluoxetine 20 mg daily as monotherapy 5

Rationale for fluoxetine monotherapy:

• Effective for depression maintenance with 4-6 day half-life providing natural protection against missed doses 4, 5
• Can be administered weekly (90 mg) if adherence issues emerge 5, 9
• Lower drug interaction potential compared to other SSRIs 1
• Well-established safety profile 10

Common Pitfalls to Avoid

1. Too-rapid benzodiazepine taper: Temazepam requires months, not weeks, for safe discontinuation 8
2. Ignoring discontinuation syndrome: SSRIs/SNRIs cause withdrawal symptoms; monitor closely during vortioxetine taper 1
3. Simultaneous multiple medication changes: Stagger discontinuations to identify source of any adverse effects
4. Inadequate non-pharmacological support: Implement CBT-Insomnia and sleep hygiene before/during medication reductions 3
5. Rigid adherence to timeline: Patient tolerance dictates pace; flexibility prevents treatment failure 8

Special Considerations for Ophthalmology Appointments

Since eye appointments are scheduled, ensure ophthalmologist is aware of:

• Current vortioxetine use (angle-closure glaucoma risk) 6
• Anticholinergic medication exposure (vision effects)
• Timeline for medication discontinuations

Request ophthalmologic evaluation for angle-closure glaucoma risk before or during vortioxetine taper 6.